Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...

Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with schizophrenia-linked cognitive ...